Table 2.

Cox model on hemorrhagic events, overall mortality and cardiovascular events at 2 years of follow-up

	Univariate analysis			Multivariate analysis*
	HR	95% CI	p value	HR	95% CI	p value
OAT vs LAA occlusion
Hemorrhagic events (1–3 months)	0.61	0.19–1.99	0.409	1.65	0.43–6.33	0.464
Hemorrhagic events (4–24 months)	3.45	0.77–15.46	0.105	6.48	1.32–31.72	0.021
				Time-interaction p value:		0.198
Overall mortality	2.22	1.20–4.11	0.011	2.76	1.31–5.86	0.008
Cardiovascular events	2.81	1.64–4.81	< 0.001	5.07	2.49–10.34	< 0.001
No-therapy vs LAA occlusion
Hemorrhagic events (1–3 months)	0.55	0.18–1.72	0.308	0.57	0.18–1.84	0.350
Hemorrhagic events (4–24 months)	3.68	0.84–16.11	0.083	4.87	1.08–21.97	0.039
				Time-interaction p value:		0.027
Overall mortality	2.40	1.32–4.35	0.004	3.09	1.59–5.98	0.001
Cardiovascular events	2.50	1.47–4.25	0.001	3.11	1.78–5.42	< 0.001

Hemorrhagic events are evaluated in the first 3 months and in the following 21 months from procedure

LAA left atrial appendage, OAT oral anticoagulant therapy

*Adjusted for gender, age, dialytic age, CHA2DS2VASc, HASBLED, type of atrial fibrillation, dyslipidemia, peripheral artery disease, previous bleeding, antiplatelet, heparin